SlideShare a Scribd company logo
Small Volume
Parenteral
Presented by:
Ajit Kumar Jha
ASU2014010100024
1st Sem. M. Pharma.
(Pharmaceutics)
School of Pharmacy
Apeejay stya university
Parenteral
Parenteral refers injectable route of
administration.
It derived from Greek words Para (Outside) and
enteron (Intestine).
So it is a route of administration other than the
alimentary canal. This route of administration
bypasses the alimentary canal.
PRIMARY PARENTERAL ROUTES
Routes Usual volume
(mL)
Needle
commonly used
Formulation
constraints
Types of medication
administered
SVP
Sub cutaneous 0.5-2 5/8 in. ,
23 gauge
Need to be isotonic Insulin, vaccines
Intra muscular 0.5-2 1.5 in. ,
23 gauge
Can be solutions,
emulsions, oils or
suspensions
Isotonic preferably
Nearly all drug
classes
Intra venous 1-100 Vein puncture
1.5 in. ,
20-22 gauge
Solutions, emulsions
and liposomes
Nearly all drug
classes
LVP 101 and larger
(infusion unit)
Venoclysis
1.5 in. ,
18-19 gauge
Solutions and some
emulsions
Nearly all drug
classes
S. No. ADVANTAGES DISVANTAGES
1. Quick onset Wrong dose or over dose can be
fatal
2. Vomiting and unconscious
patients can take
Pain at site
3. Prolonged action by
modified formulation
( Depot)
Trained person required
4. Nutritive fluids (glucose,
electrolytes) can be given
Expensive
5. Drugs with poor absorption
or instability from GIT
NECESSITY OF ASEPTIC
CONDITIONS IN PRODUCTION,
COMPOUNDING AND
ADMINISTRATION
Small Volume Parenteral
• According to USP : “ an injection that is
packaged in containers labelled as containing
100 ml or less”
INTRODUCTION :
• All the sterile products packaged in vials, ampoules,
cartridges, syringes, bottles or any other container
that is 100ml or less fall under the class of SVP.
• Ophthalmic products packaged in squeezable
plastic containers, although topically applied to the
eye rather than administered by injection, also fall
under the classification of Small Volume Injections
(SVI) as long as the container size is 100ml or less.
• SVP aqueous solutions can be administered by
intravenous route because of local irritation. Small
volume parenteral products can be formulated and
packaged in several ways and include a wide
variety of products like :
• Pharmaceutical products, Biological products,
Allergenic extracts, Radiopharmaceutical products,
Genetically engineered or biotechnology products,
Liposome and lipid products.
• An injection is a preparation intended for
parenteral administration and/or for constituting
or diluting a parenteral article prior to
administration
• Types of preparations :-
 Drug injection
 Drug for injection
 Drug injectable emulsion
 Drug injectable suspension
 Drug for injectable suspension
Contd…….
• Definition:- According to the USP 24/ NF 19 “As those
preparations intended for injection through the skin or
other external boundary tissue, rather than through the
alimentary canal”
• so that the active substance they contain are
administered using gravity or force directly into a blood
vessel,organ,tissue or lesion.
Containers:
1. Glass:
• Highly Resistant Borosilicate Glass
• Treated Soda lime Glass
• Regular Soda Lime Glass
• N.P (Non-parenteral) Glass
Type 4 is not used for parenteral packaging,
others all are used for parenteral packaging.
Contd…….
2. Plastic:
Plastic containers are used but they face following problems
• Permeation
• Sorption
• Leaching
• Softening
3. Rubber:
To provide closure for multiple dose vials, IV fluid bottles, plugs for disposable syringes and bulbs for
ophthalmic pipettes, rubber is the material of choice.
Problems associated with rubber closures are
• Incompatibility
• Chemical instability
• Physical instability
Closure:
• Characteristics of Good Pharmaceutical rubbers
• Good ageing qualities
• Satisfactory hardness and elasticity
• Resistance to sterilization conditions
• Impermeable to moisture and air
• Examples:
• Butyl Rubbers
• Natural Rubbers
• Neoprene Rubbers
• Polyisoprene rubbers
• Silicone Rubbers
SYSTEM
COMPONE
NT
Preparatio
n
Area
Storage
Area
Personnel
Policies
and
Procedures
Admixture
system
PROCESSING OF
PARENTERALS
S.No. STEPS
1. Cleaning of containers, closures and equipments
2. Collection of materials
3. Preparation of parenteral products
4. Filtration
5. Filling the preparation in final containers
6. Sealing the containers
7. Sterilization
8. Evaluation of parenteral preparation
9. Labeling and packaging
Formulation of parenteral
products
• In the preparation of parenteral products, the following substances
are added to make a stable preparation:
 The active drug
 Vehicles
 Aqueous vehicle (e.g. water for injection, water for injection free from CO2
)
 Non-aqueous vehicle (e.g. Ethyl alcohol, propylene glycol, almond oil)
 Adjuvants
 Solubilizing agents (e.g. Tweens & polysorbates)
 Stabilizers & antioxidants (e.g. thiourea, ascorbic acid, tocopherol)
 Buffering agents (e.g. citric acid, sodium citrate)
 Antibacterial agents (e.g. benzyl alcohol, metacresol, phenol)
 Chelating agents (e.g. EDTA)
 Suspending, emulsifying & wetting agents (e.g. MC, CMC)
 Tonicity factor (e.g. sodium chloride, dextrose)
Formulation of SVP :
• Aqueous vehicle :
• Types :- purified water, WFI, sterile WFI,
bacteriostatic WFI, sterile WF Irrigation.
• Preparation :- Distillation, ion exchange or
reverse osmosis.
• Except purified water all are pyrogen free
• Non aqueous vehicle :
• Because of safety
purity
biocompatibility
 Several SVPs are marketed as oily solutions
The oil must be vegetable in origin (sesame, olive, or
cottonseed oil).
Product USP Oil
Ampicillin(suspension) Vegetable
Diethyl stilbestrol Sesame, cotton
Epinephrine(suspension) Sesame
Penicillin G procaine Vegetable
(suspension)
 Co solvents :-
Are used to increase the stability of poorly soluble drug
in water and prevent drug chemical degradation by
hydrolysis.
Eg. propylene glycol or in combination with ethanol and
polyethylene glycol.
Ingredients or added substances
• Antimicrobial preservatives :
• Maintain the stability of the product during
storage.
• Phenylmercuric nitrate and Thimerosal
0.001% , Benzethonium chloride 0.01%,
Benzyl alcohol 0.5- 10.0%, Phenol or cresol
0.5%, chlorobutanol 0.5%.
• Buffers :
• Added to maintain pH Results in stability of
drug against hydrolytic degradation or
enhance the solubility of drug in solution.
• Common buffers used in SVPs
pH Buffer system Conc. %
3.5-5.7 Acetic acid-acetate 0.22
2.5-6.0 Citric acid-citrate 0.5
6.0-8.2 Phosphoric acid- 0.8-2
phosphate
8.2-10.2 Glutamic acid- 1-2
glutamate
 Antioxidants :
Antioxidants function by preferentially with molecular oxygen and
minimizing or terminating the free radical auto-oxidation
reaction.
eg. Reducing agents: Ascorbic acid 0.02-0.1%, Sodium
Bisulfite 0.1-0.15%, Thiourea 0.005%
Blocking agents: Ascorbic acid esters 0.01-0.015%,
Tocopherols 0.05-0.075%
• Tonicity adjusters :
• Electrolytes: Nacl
• Non electrolytes: Glucose, Mannitol, Glycerine
• Eg. Of isotonic: Dextrose injection 5% & Nacl
injection 0.9%
• Some solutions are iso-osmotic but not isotonic
this is because the physiology of the cell
membranes must be considered.
• For eg. the cell membrane of the RBC is not semi-
permeable to all drugs it allows ammonium
chloride, alcohol, boric acid, glycerin, propylene
glycol, and urea to diffuse freely.
• In the eye the cell membrane is semi permeable to
boric acid and a 2% solution is an isotonic
ophthalmic solution.
• But even though a 2% solution of boric acid is an
isotonic with the eye and is iso-osmotic, it is not
isotonic with blood since boric acid can freely diffuse
through the RBC– and it may cause HEMOLYSIS.
• Tonicity can be measurement by: osmometer
• Other ingredients :
• Bulking agents – for freeze dried preparations(solids) eg
mannitol, lactose sucrose, dextrose.
• Suspending agents – Carboxy methyl cellulose, sorbitol.
• Emulsifying agents – lecithin, polysorbate 80
• Ophthalmic ointments bases – petrolatum.
Production facilities of parenterals
• The production area where the parenteral
preparation are manufactured can be divided
into five sections:
Clean-up area
Preparation area
Aseptic area
Quarantine area
Finishing & packaging area
Contd…….
Clean-up area:
 It is not aseptic area.
 All the parenteral products must be free from foreign particles &
microorganism.
 Clean-up area should be withstand moisture, dust & detergent.
 This area should be kept clean so that contaminants may not be carried
out into aseptic area.
Preparation area:
 In this area the ingredients of the parenteral preparation are mixed &
preparation is made for filling operation.
 It is not essentially aseptic area but strict precautions are required to
prevent any contamination from outside.
Contd…….
Aseptic area:
 The parenteral preparations are filtered, filled into final
container & sealed should be in aseptic area.
 The entry of personnel into aseptic area should be limited &
through an air lock.
 Ceiling, wall & floor of that area should be sealed & painted.
 The air in the aseptic area should be free from fibers, dust and
microorganism.
 The High efficiency particulate air filters (HEPA) is used for air.
 UV lamps are fitted in order to maintain sterility.
Contd…….
Quarantine area:
 After filling, sealing & sterilization the parenteral
product are held up in quarantine area.
 Randomly samples were kept foe evaluation.
 The batch or product pass the evaluation tests are
transfer in to finishing or packaging area.
Finishing & packaging area:
 Parenteral products are properly labelled and packed.
 Properly packing is essential to provide protection
against physical damage.
 The labelled container should be packed in cardboard
or plastic container.
 Ampoules should be packed in partitioned boxes
EVALUATION OF PARENTERAL
PREPARATIONS
• The finished parenteral products are subjected to
the following tests, in order to maintain quality
control:
• A) sterility test
• B)clarity test
• C)leakage test
• D)pyrogen test
• E)assay
A) sterility test
• It is a procedure carried out to detect and
conform absence of any viable form of microbes
in or on pharmacopeia preparation or product.
1) Method of sterility testing
i ) METHOD 1 Membrane filtration method
ii) METHOD 2 Direct inoculation method
Membrane filtration method
(METHOD 1):
 Membrane filtration Appropriate for : (advantage)
• Filterable aqueous preparations
• Alcoholic preparations
• Oily preparations
• Preparations miscible with or soluble in aqueous or oily
(solvents with no antimicrobial effect)
 All steps of this procedure are performed aseptically in a
Class 100 Laminar Flow Hood
Composition of culture medium for
sterility testing
Fluid
Thioglycollate
Soybean- casein
digest
L- cystine 0.5gm -
Sodium chloride 2.5gm 5.0gm
Dextrose 5.0/5.5gm 2.3/2.5gm
Pancreatic digest of casein 15.0gm 17.0gm
Papaic digest of soya bean - 3.0gm
Dibasic potassium phosphate - 2.5gm
Granular agar (moisture<15%) 0.75gm -
Yeast extract (water soluble) 5.0gm -
Sodium thioglycollate or
thioglycolic acid
0.5gm or
0.3ml
-
Resazurin (0.10%w/v fresh
solution)
1.0ml -
Purified water 1000ml 1000ml
Components Culture medium
Membrane filter 0.45μ porosity
Filter the test solution
After filtration remove the filter
Cut the filter in to two halves
First halves (For Bacteria) Second halves (For Fungi)
Transfer in 100 ml culture media
(Fluid Thioglycollate medium)
Incubate at 30-350 C for not less then 7 days
Transfer in 100 ml culture media
(Soyabeans-Casein Digest medium)
Incubate at 20-250 C for not less then 14 days
Observe the growth in the media Observe the growth in the media
Direct inoculation method (METHOD
2):
 Suitable for samples with small volumes
 volume of the product is not more than 10% of
the volume of the medium
 suitable method for aqueous solutions, oily
liquids, ointments and creams
 Direct inoculation of the culture medium suitable
quantity of the preparation to be examined is
transferred directly into the appropriate culture
medium & incubate for not less than 14 days.
B)clarity test
• Particulate matter is defined as unwanted mobile insoluble
matter other than gas bubble present in the product.
• If the particle size of foreign matter is larger than the size
of R.B.C.. It can block the blood vessel.
• The permit limits of particulate matter as per I.P. are
follows:
Methods for monitoring particulate
matter contamination:
1) Visual method
2) Coulter counter method
3) Filtration method
4) Light blockage method
C)leakage test
• The sealed ampoules are subjected to small cracks which
occur due to rapid temperature changes or due to
mechanical shocks.
Filled & sealed ampoules
Dipped in 1% Methylene blue solution
Under negative pressure in vacuum chamber
Vacuum released colored solution enter into the ampoule
Defective sealing
Vials & bottles are not suitable for this test because the
sealing material used is not rigid
D)pyrogen test
 Pyrogen = “Pyro” (Greek = Fire) + “gen” (Greek
= beginning).
 Fever producing, metabolic by-products of
microbial growth and death.
 Bacterial pyrogens are called “Endotoxins”.
Gram negative bacteria produce more potent
endotoxins than gram + bacteria and fungi.
 Endotoxins are heat stable lipopolysaccharides
(LPS) present in bacterial cell walls, not present
in cell-free bacterial filtrates
Method
 Dissolve the subs being examined in, or dilute it with a pyrogen free saline
solution
 Warm the liquid being examined to approx. 38.5o C temp before injection
 The volume of injection is NLT 0.5ml/kg & NMT 10ml/kg of body weight
 Withhold water during test
 Clinical thermometer is inserted into the rectum of rabbit to record body
temp
 2 normal reading of rectal temp are should be taken prior to the test
injection at an interval of half an hr & its mean is calculated- initial temp
 The solution under test is injected through an ear vein
 Record the temp of each rabbit in an interval of 30 min for 3 hrs
 The difference between initial temp & maximum temp is recorded- taken
as response
Limulus amebocyte lysate [LAL]
test
• Limulus amebocyte lysate [LAL] test another method
for the determination of pyrogenic endotoxins
• In this method the test solution is combined with a
cell lysate from the ameabocyte [blood cells] of horse
shoe crab
• Any endo toxin that might be present will be
coagulated with protien fraction of the ameabocytes
and results in the formation of a gel
• This consider to be simple,rapid and of greater
sensitivity that the rabbit test
E)assay
• Assay is performed according to method given In
the monograph of that parental preperation in
the pharmacopoeia
• Assay is done to check the quantity of
medicament present in the parenteral
preperation
References
• Lachman/Lieberman’s “The Theory and Practice Of Industrial
Pharmacy” Fourth Edition 2013, Edited by: Roop K Khar, SP
Vyas, Farhan J Ahmad, Gaurav K Jain, CBS Publishers and
Distributors Pvt Ltd, New Delhi.
• Doornbos C and Hann P. Optimization Techniques in Formulation
and Processing. In Encyclopedia of Pharmaceutical Technology.
Swarbrick J and Boylan JC, Eds., Vol. II, Marcel Dekker, New
York. 199
• Modern Pharmaceutics Fourth Edition, Revised and Expanded,
Edited By G.S.Banker & C.T.Rhodes, Marcel Dekker pg387-389.
• The Science & practice of Pharmacy, By Remington, Vol-01,
21st Edition, Lippincott Publication, pg-838-840.
Thank You……..

More Related Content

What's hot

General requirements of parenteral preparations
General requirements of parenteral preparationsGeneral requirements of parenteral preparations
Parenteral production
Parenteral   productionParenteral   production
Parenteral productionceutics1315
 
IVIVC
IVIVCIVIVC
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
Sourav Kar
 
Liquid manufacturing
Liquid manufacturingLiquid manufacturing
Liquid manufacturing
Dr. Supriya Suman
 
Microcapsules and microspheres
Microcapsules and microspheresMicrocapsules and microspheres
Microcapsules and microspheres
SNJBs SSDJ College of Pharmacy, Chandwad
 
factors affecting dissolution rate a full view.
 factors affecting dissolution rate a full view. factors affecting dissolution rate a full view.
factors affecting dissolution rate a full view.
aishwaryashiremath
 
Formulation of small & large volume parenteral
Formulation of small & large  volume parenteral Formulation of small & large  volume parenteral
Formulation of small & large volume parenteral
SagarBhor5
 
Formulation & Development of Aerosol
Formulation & Development of AerosolFormulation & Development of Aerosol
Formulation & Development of Aerosol
Ashutosh Panke
 
Pellets
PelletsPellets
Theories of Dissolution
Theories of DissolutionTheories of Dissolution
Theories of Dissolution
PRASHANT DEORE
 
Parentrals
ParentralsParentrals
Parentrals
Pallavi Kurra
 
Microencapsulation (2)
Microencapsulation (2)Microencapsulation (2)
Microencapsulation (2)Shivaram
 
In vitro Dissolution Testing Models
In vitro Dissolution Testing ModelsIn vitro Dissolution Testing Models
In vitro Dissolution Testing Models
Ameer Ahmed
 
Evaluation of capules
Evaluation of capulesEvaluation of capules
Evaluation of capules
Shaik Sana
 
Parameters in Preformulation Studies
Parameters in Preformulation StudiesParameters in Preformulation Studies
Parameters in Preformulation Studies
Cognibrain Healthcare
 
EMULGEL
EMULGELEMULGEL
IN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATIONIN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATION
N Anusha
 

What's hot (20)

General requirements of parenteral preparations
General requirements of parenteral preparationsGeneral requirements of parenteral preparations
General requirements of parenteral preparations
 
Parenteral production
Parenteral   productionParenteral   production
Parenteral production
 
IVIVC
IVIVCIVIVC
IVIVC
 
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
 
Liquid manufacturing
Liquid manufacturingLiquid manufacturing
Liquid manufacturing
 
Microcapsules and microspheres
Microcapsules and microspheresMicrocapsules and microspheres
Microcapsules and microspheres
 
factors affecting dissolution rate a full view.
 factors affecting dissolution rate a full view. factors affecting dissolution rate a full view.
factors affecting dissolution rate a full view.
 
Formulation of small & large volume parenteral
Formulation of small & large  volume parenteral Formulation of small & large  volume parenteral
Formulation of small & large volume parenteral
 
Small volume parenterals
Small volume parenteralsSmall volume parenterals
Small volume parenterals
 
Formulation & Development of Aerosol
Formulation & Development of AerosolFormulation & Development of Aerosol
Formulation & Development of Aerosol
 
Pellets
PelletsPellets
Pellets
 
Theories of Dissolution
Theories of DissolutionTheories of Dissolution
Theories of Dissolution
 
Parentrals
ParentralsParentrals
Parentrals
 
Microencapsulation (2)
Microencapsulation (2)Microencapsulation (2)
Microencapsulation (2)
 
In vitro Dissolution Testing Models
In vitro Dissolution Testing ModelsIn vitro Dissolution Testing Models
In vitro Dissolution Testing Models
 
Evaluation of capules
Evaluation of capulesEvaluation of capules
Evaluation of capules
 
Niosome
Niosome Niosome
Niosome
 
Parameters in Preformulation Studies
Parameters in Preformulation StudiesParameters in Preformulation Studies
Parameters in Preformulation Studies
 
EMULGEL
EMULGELEMULGEL
EMULGEL
 
IN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATIONIN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATION
 

Similar to Small volume parenteral .......

Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug deliveryGaurav Kr
 
11 sterile dosage form
11 sterile dosage form11 sterile dosage form
11 sterile dosage form
Pradeep Patil
 
Parenteral by SV Deshmane
Parenteral by SV DeshmaneParenteral by SV Deshmane
Parenteral by SV Deshmane
Subhash Deshmane
 
Parenterals
ParenteralsParenterals
Parenterals
Rameshwar Madharia
 
Types of Parenteral Formulation
Types of Parenteral FormulationTypes of Parenteral Formulation
Types of Parenteral Formulation
NIDHIBANSAL65
 
Sterile Products & admixtures
Sterile Products & admixturesSterile Products & admixtures
Sterile Products & admixtures
Rameshwar Madharia
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
Ravish Yadav
 
PARENTRAL PRODUCT .ppt
PARENTRAL PRODUCT .pptPARENTRAL PRODUCT .ppt
PARENTRAL PRODUCT .ppt
ANKITRAJ370351
 
5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf
SaqibTeli1
 
Parentrals
Parentrals Parentrals
Parentrals
Naresh Gorantla
 
Preparation & Stability of Large Volume Parenterals by PRINCE THAKUR
Preparation & Stability of Large Volume Parenterals by PRINCE THAKURPreparation & Stability of Large Volume Parenterals by PRINCE THAKUR
Preparation & Stability of Large Volume Parenterals by PRINCE THAKUR
PrinceThakur50
 
Large & Small Volume Parenteral
Large & Small Volume ParenteralLarge & Small Volume Parenteral
Large & Small Volume Parenteral
SreePrakashPandey
 
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Dr. Jigar Vyas
 
Parenterals
ParenteralsParenterals
Parenterals
Amruta Balekundri
 
UNIT- 4 (PARENTERAL PRODUCTS).pptx
UNIT- 4  (PARENTERAL PRODUCTS).pptxUNIT- 4  (PARENTERAL PRODUCTS).pptx
UNIT- 4 (PARENTERAL PRODUCTS).pptx
ArunRaina18
 
Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentrals
ROHIT
 
Preparation of large volume and small volume parenteral
Preparation of large volume and small volume parenteralPreparation of large volume and small volume parenteral
Preparation of large volume and small volume parenteral
sangram maskar
 
Parenteral preparation, equipments and layout
Parenteral preparation, equipments and layoutParenteral preparation, equipments and layout
Parenteral preparation, equipments and layout
swapnil_pharmacist
 

Similar to Small volume parenteral ....... (20)

Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
 
11 sterile dosage form
11 sterile dosage form11 sterile dosage form
11 sterile dosage form
 
Pilot plant parenteal production
Pilot plant parenteal productionPilot plant parenteal production
Pilot plant parenteal production
 
Parenteral by SV Deshmane
Parenteral by SV DeshmaneParenteral by SV Deshmane
Parenteral by SV Deshmane
 
Parenterals
ParenteralsParenterals
Parenterals
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
 
Types of Parenteral Formulation
Types of Parenteral FormulationTypes of Parenteral Formulation
Types of Parenteral Formulation
 
Sterile Products & admixtures
Sterile Products & admixturesSterile Products & admixtures
Sterile Products & admixtures
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
 
PARENTRAL PRODUCT .ppt
PARENTRAL PRODUCT .pptPARENTRAL PRODUCT .ppt
PARENTRAL PRODUCT .ppt
 
5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf
 
Parentrals
Parentrals Parentrals
Parentrals
 
Preparation & Stability of Large Volume Parenterals by PRINCE THAKUR
Preparation & Stability of Large Volume Parenterals by PRINCE THAKURPreparation & Stability of Large Volume Parenterals by PRINCE THAKUR
Preparation & Stability of Large Volume Parenterals by PRINCE THAKUR
 
Large & Small Volume Parenteral
Large & Small Volume ParenteralLarge & Small Volume Parenteral
Large & Small Volume Parenteral
 
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
 
Parenterals
ParenteralsParenterals
Parenterals
 
UNIT- 4 (PARENTERAL PRODUCTS).pptx
UNIT- 4  (PARENTERAL PRODUCTS).pptxUNIT- 4  (PARENTERAL PRODUCTS).pptx
UNIT- 4 (PARENTERAL PRODUCTS).pptx
 
Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentrals
 
Preparation of large volume and small volume parenteral
Preparation of large volume and small volume parenteralPreparation of large volume and small volume parenteral
Preparation of large volume and small volume parenteral
 
Parenteral preparation, equipments and layout
Parenteral preparation, equipments and layoutParenteral preparation, equipments and layout
Parenteral preparation, equipments and layout
 

Recently uploaded

KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 

Small volume parenteral .......

  • 1. Small Volume Parenteral Presented by: Ajit Kumar Jha ASU2014010100024 1st Sem. M. Pharma. (Pharmaceutics) School of Pharmacy Apeejay stya university
  • 2. Parenteral Parenteral refers injectable route of administration. It derived from Greek words Para (Outside) and enteron (Intestine). So it is a route of administration other than the alimentary canal. This route of administration bypasses the alimentary canal.
  • 3. PRIMARY PARENTERAL ROUTES Routes Usual volume (mL) Needle commonly used Formulation constraints Types of medication administered SVP Sub cutaneous 0.5-2 5/8 in. , 23 gauge Need to be isotonic Insulin, vaccines Intra muscular 0.5-2 1.5 in. , 23 gauge Can be solutions, emulsions, oils or suspensions Isotonic preferably Nearly all drug classes Intra venous 1-100 Vein puncture 1.5 in. , 20-22 gauge Solutions, emulsions and liposomes Nearly all drug classes LVP 101 and larger (infusion unit) Venoclysis 1.5 in. , 18-19 gauge Solutions and some emulsions Nearly all drug classes
  • 4. S. No. ADVANTAGES DISVANTAGES 1. Quick onset Wrong dose or over dose can be fatal 2. Vomiting and unconscious patients can take Pain at site 3. Prolonged action by modified formulation ( Depot) Trained person required 4. Nutritive fluids (glucose, electrolytes) can be given Expensive 5. Drugs with poor absorption or instability from GIT NECESSITY OF ASEPTIC CONDITIONS IN PRODUCTION, COMPOUNDING AND ADMINISTRATION
  • 5. Small Volume Parenteral • According to USP : “ an injection that is packaged in containers labelled as containing 100 ml or less”
  • 6. INTRODUCTION : • All the sterile products packaged in vials, ampoules, cartridges, syringes, bottles or any other container that is 100ml or less fall under the class of SVP. • Ophthalmic products packaged in squeezable plastic containers, although topically applied to the eye rather than administered by injection, also fall under the classification of Small Volume Injections (SVI) as long as the container size is 100ml or less. • SVP aqueous solutions can be administered by intravenous route because of local irritation. Small volume parenteral products can be formulated and packaged in several ways and include a wide variety of products like :
  • 7. • Pharmaceutical products, Biological products, Allergenic extracts, Radiopharmaceutical products, Genetically engineered or biotechnology products, Liposome and lipid products. • An injection is a preparation intended for parenteral administration and/or for constituting or diluting a parenteral article prior to administration • Types of preparations :-  Drug injection  Drug for injection  Drug injectable emulsion  Drug injectable suspension  Drug for injectable suspension
  • 8. Contd……. • Definition:- According to the USP 24/ NF 19 “As those preparations intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal” • so that the active substance they contain are administered using gravity or force directly into a blood vessel,organ,tissue or lesion.
  • 9. Containers: 1. Glass: • Highly Resistant Borosilicate Glass • Treated Soda lime Glass • Regular Soda Lime Glass • N.P (Non-parenteral) Glass Type 4 is not used for parenteral packaging, others all are used for parenteral packaging.
  • 10. Contd……. 2. Plastic: Plastic containers are used but they face following problems • Permeation • Sorption • Leaching • Softening 3. Rubber: To provide closure for multiple dose vials, IV fluid bottles, plugs for disposable syringes and bulbs for ophthalmic pipettes, rubber is the material of choice. Problems associated with rubber closures are • Incompatibility • Chemical instability • Physical instability
  • 11. Closure: • Characteristics of Good Pharmaceutical rubbers • Good ageing qualities • Satisfactory hardness and elasticity • Resistance to sterilization conditions • Impermeable to moisture and air • Examples: • Butyl Rubbers • Natural Rubbers • Neoprene Rubbers • Polyisoprene rubbers • Silicone Rubbers
  • 13. PROCESSING OF PARENTERALS S.No. STEPS 1. Cleaning of containers, closures and equipments 2. Collection of materials 3. Preparation of parenteral products 4. Filtration 5. Filling the preparation in final containers 6. Sealing the containers 7. Sterilization 8. Evaluation of parenteral preparation 9. Labeling and packaging
  • 14. Formulation of parenteral products • In the preparation of parenteral products, the following substances are added to make a stable preparation:  The active drug  Vehicles  Aqueous vehicle (e.g. water for injection, water for injection free from CO2 )  Non-aqueous vehicle (e.g. Ethyl alcohol, propylene glycol, almond oil)  Adjuvants  Solubilizing agents (e.g. Tweens & polysorbates)  Stabilizers & antioxidants (e.g. thiourea, ascorbic acid, tocopherol)  Buffering agents (e.g. citric acid, sodium citrate)  Antibacterial agents (e.g. benzyl alcohol, metacresol, phenol)  Chelating agents (e.g. EDTA)  Suspending, emulsifying & wetting agents (e.g. MC, CMC)  Tonicity factor (e.g. sodium chloride, dextrose)
  • 15. Formulation of SVP : • Aqueous vehicle : • Types :- purified water, WFI, sterile WFI, bacteriostatic WFI, sterile WF Irrigation. • Preparation :- Distillation, ion exchange or reverse osmosis. • Except purified water all are pyrogen free • Non aqueous vehicle : • Because of safety purity biocompatibility  Several SVPs are marketed as oily solutions
  • 16. The oil must be vegetable in origin (sesame, olive, or cottonseed oil). Product USP Oil Ampicillin(suspension) Vegetable Diethyl stilbestrol Sesame, cotton Epinephrine(suspension) Sesame Penicillin G procaine Vegetable (suspension)  Co solvents :- Are used to increase the stability of poorly soluble drug in water and prevent drug chemical degradation by hydrolysis. Eg. propylene glycol or in combination with ethanol and polyethylene glycol.
  • 17. Ingredients or added substances • Antimicrobial preservatives : • Maintain the stability of the product during storage. • Phenylmercuric nitrate and Thimerosal 0.001% , Benzethonium chloride 0.01%, Benzyl alcohol 0.5- 10.0%, Phenol or cresol 0.5%, chlorobutanol 0.5%. • Buffers : • Added to maintain pH Results in stability of drug against hydrolytic degradation or enhance the solubility of drug in solution.
  • 18. • Common buffers used in SVPs pH Buffer system Conc. % 3.5-5.7 Acetic acid-acetate 0.22 2.5-6.0 Citric acid-citrate 0.5 6.0-8.2 Phosphoric acid- 0.8-2 phosphate 8.2-10.2 Glutamic acid- 1-2 glutamate  Antioxidants : Antioxidants function by preferentially with molecular oxygen and minimizing or terminating the free radical auto-oxidation reaction. eg. Reducing agents: Ascorbic acid 0.02-0.1%, Sodium Bisulfite 0.1-0.15%, Thiourea 0.005% Blocking agents: Ascorbic acid esters 0.01-0.015%, Tocopherols 0.05-0.075%
  • 19. • Tonicity adjusters : • Electrolytes: Nacl • Non electrolytes: Glucose, Mannitol, Glycerine • Eg. Of isotonic: Dextrose injection 5% & Nacl injection 0.9% • Some solutions are iso-osmotic but not isotonic this is because the physiology of the cell membranes must be considered. • For eg. the cell membrane of the RBC is not semi- permeable to all drugs it allows ammonium chloride, alcohol, boric acid, glycerin, propylene glycol, and urea to diffuse freely. • In the eye the cell membrane is semi permeable to boric acid and a 2% solution is an isotonic ophthalmic solution.
  • 20. • But even though a 2% solution of boric acid is an isotonic with the eye and is iso-osmotic, it is not isotonic with blood since boric acid can freely diffuse through the RBC– and it may cause HEMOLYSIS. • Tonicity can be measurement by: osmometer • Other ingredients : • Bulking agents – for freeze dried preparations(solids) eg mannitol, lactose sucrose, dextrose. • Suspending agents – Carboxy methyl cellulose, sorbitol. • Emulsifying agents – lecithin, polysorbate 80 • Ophthalmic ointments bases – petrolatum.
  • 21. Production facilities of parenterals • The production area where the parenteral preparation are manufactured can be divided into five sections: Clean-up area Preparation area Aseptic area Quarantine area Finishing & packaging area
  • 22. Contd……. Clean-up area:  It is not aseptic area.  All the parenteral products must be free from foreign particles & microorganism.  Clean-up area should be withstand moisture, dust & detergent.  This area should be kept clean so that contaminants may not be carried out into aseptic area. Preparation area:  In this area the ingredients of the parenteral preparation are mixed & preparation is made for filling operation.  It is not essentially aseptic area but strict precautions are required to prevent any contamination from outside.
  • 23. Contd……. Aseptic area:  The parenteral preparations are filtered, filled into final container & sealed should be in aseptic area.  The entry of personnel into aseptic area should be limited & through an air lock.  Ceiling, wall & floor of that area should be sealed & painted.  The air in the aseptic area should be free from fibers, dust and microorganism.  The High efficiency particulate air filters (HEPA) is used for air.  UV lamps are fitted in order to maintain sterility.
  • 24. Contd……. Quarantine area:  After filling, sealing & sterilization the parenteral product are held up in quarantine area.  Randomly samples were kept foe evaluation.  The batch or product pass the evaluation tests are transfer in to finishing or packaging area. Finishing & packaging area:  Parenteral products are properly labelled and packed.  Properly packing is essential to provide protection against physical damage.  The labelled container should be packed in cardboard or plastic container.  Ampoules should be packed in partitioned boxes
  • 25. EVALUATION OF PARENTERAL PREPARATIONS • The finished parenteral products are subjected to the following tests, in order to maintain quality control: • A) sterility test • B)clarity test • C)leakage test • D)pyrogen test • E)assay
  • 26. A) sterility test • It is a procedure carried out to detect and conform absence of any viable form of microbes in or on pharmacopeia preparation or product. 1) Method of sterility testing i ) METHOD 1 Membrane filtration method ii) METHOD 2 Direct inoculation method
  • 27. Membrane filtration method (METHOD 1):  Membrane filtration Appropriate for : (advantage) • Filterable aqueous preparations • Alcoholic preparations • Oily preparations • Preparations miscible with or soluble in aqueous or oily (solvents with no antimicrobial effect)  All steps of this procedure are performed aseptically in a Class 100 Laminar Flow Hood
  • 28. Composition of culture medium for sterility testing Fluid Thioglycollate Soybean- casein digest L- cystine 0.5gm - Sodium chloride 2.5gm 5.0gm Dextrose 5.0/5.5gm 2.3/2.5gm Pancreatic digest of casein 15.0gm 17.0gm Papaic digest of soya bean - 3.0gm Dibasic potassium phosphate - 2.5gm Granular agar (moisture<15%) 0.75gm - Yeast extract (water soluble) 5.0gm - Sodium thioglycollate or thioglycolic acid 0.5gm or 0.3ml - Resazurin (0.10%w/v fresh solution) 1.0ml - Purified water 1000ml 1000ml Components Culture medium
  • 29. Membrane filter 0.45μ porosity Filter the test solution After filtration remove the filter Cut the filter in to two halves First halves (For Bacteria) Second halves (For Fungi) Transfer in 100 ml culture media (Fluid Thioglycollate medium) Incubate at 30-350 C for not less then 7 days Transfer in 100 ml culture media (Soyabeans-Casein Digest medium) Incubate at 20-250 C for not less then 14 days Observe the growth in the media Observe the growth in the media
  • 30. Direct inoculation method (METHOD 2):  Suitable for samples with small volumes  volume of the product is not more than 10% of the volume of the medium  suitable method for aqueous solutions, oily liquids, ointments and creams  Direct inoculation of the culture medium suitable quantity of the preparation to be examined is transferred directly into the appropriate culture medium & incubate for not less than 14 days.
  • 31. B)clarity test • Particulate matter is defined as unwanted mobile insoluble matter other than gas bubble present in the product. • If the particle size of foreign matter is larger than the size of R.B.C.. It can block the blood vessel. • The permit limits of particulate matter as per I.P. are follows:
  • 32. Methods for monitoring particulate matter contamination: 1) Visual method 2) Coulter counter method 3) Filtration method 4) Light blockage method
  • 33. C)leakage test • The sealed ampoules are subjected to small cracks which occur due to rapid temperature changes or due to mechanical shocks. Filled & sealed ampoules Dipped in 1% Methylene blue solution Under negative pressure in vacuum chamber Vacuum released colored solution enter into the ampoule Defective sealing Vials & bottles are not suitable for this test because the sealing material used is not rigid
  • 34. D)pyrogen test  Pyrogen = “Pyro” (Greek = Fire) + “gen” (Greek = beginning).  Fever producing, metabolic by-products of microbial growth and death.  Bacterial pyrogens are called “Endotoxins”. Gram negative bacteria produce more potent endotoxins than gram + bacteria and fungi.  Endotoxins are heat stable lipopolysaccharides (LPS) present in bacterial cell walls, not present in cell-free bacterial filtrates
  • 35. Method  Dissolve the subs being examined in, or dilute it with a pyrogen free saline solution  Warm the liquid being examined to approx. 38.5o C temp before injection  The volume of injection is NLT 0.5ml/kg & NMT 10ml/kg of body weight  Withhold water during test  Clinical thermometer is inserted into the rectum of rabbit to record body temp  2 normal reading of rectal temp are should be taken prior to the test injection at an interval of half an hr & its mean is calculated- initial temp  The solution under test is injected through an ear vein  Record the temp of each rabbit in an interval of 30 min for 3 hrs  The difference between initial temp & maximum temp is recorded- taken as response
  • 36. Limulus amebocyte lysate [LAL] test • Limulus amebocyte lysate [LAL] test another method for the determination of pyrogenic endotoxins • In this method the test solution is combined with a cell lysate from the ameabocyte [blood cells] of horse shoe crab • Any endo toxin that might be present will be coagulated with protien fraction of the ameabocytes and results in the formation of a gel • This consider to be simple,rapid and of greater sensitivity that the rabbit test
  • 37. E)assay • Assay is performed according to method given In the monograph of that parental preperation in the pharmacopoeia • Assay is done to check the quantity of medicament present in the parenteral preperation
  • 38. References • Lachman/Lieberman’s “The Theory and Practice Of Industrial Pharmacy” Fourth Edition 2013, Edited by: Roop K Khar, SP Vyas, Farhan J Ahmad, Gaurav K Jain, CBS Publishers and Distributors Pvt Ltd, New Delhi. • Doornbos C and Hann P. Optimization Techniques in Formulation and Processing. In Encyclopedia of Pharmaceutical Technology. Swarbrick J and Boylan JC, Eds., Vol. II, Marcel Dekker, New York. 199 • Modern Pharmaceutics Fourth Edition, Revised and Expanded, Edited By G.S.Banker & C.T.Rhodes, Marcel Dekker pg387-389. • The Science & practice of Pharmacy, By Remington, Vol-01, 21st Edition, Lippincott Publication, pg-838-840.